Progenics Pharmaceuticals
(PGNX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2007 | 06-2007 | 03-2007 | 12-2006 | 09-2006 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -28,416 | -12,816 | -10,433 | -21,618 | -19,906 |
| Depreciation Amortization | 1,790 | 1,076 | 443 | 1,544 | 1,133 |
| Accounts receivable | -505 | -323 | N/A | 1,588 | 301 |
| Other Working Capital | -10,081 | -6,326 | -3,792 | -15,069 | -13,783 |
| Other Operating Activity | 12,345 | 5,997 | 2,948 | 24,398 | 22,163 |
| Operating Cash Flow | $-24,867 | $-12,392 | $-10,834 | $-9,157 | $-10,092 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 18,432 | 33,249 | 17,389 | -31,141 | -28,213 |
| PPE Investments | -4,359 | -2,142 | -1,067 | -8,768 | -6,511 |
| Net Acquisitions | N/A | N/A | N/A | -13,128 | -13,128 |
| Other Investing Activity | -5 | -4 | -2 | -6 | -5 |
| Investing Cash Flow | $14,068 | $31,103 | $16,320 | $-53,043 | $-47,857 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 66,297 | 4,422 | 2,804 | 7,075 | 5,309 |
| Common Stock Repurchased | -19 | -19 | N/A | N/A | N/A |
| Other Financing Activity | -3,058 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | $63,220 | $4,403 | $2,804 | $7,075 | $5,309 |
| Beginning Cash Position | 11,947 | 11,947 | 11,947 | 67,072 | 67,072 |
| End Cash Position | 64,368 | 35,061 | 20,237 | 11,947 | 14,432 |
| Net Cash Flow | $52,421 | $23,114 | $8,290 | $-55,125 | $-52,640 |
| Free Cash Flow | |||||
| Operating Cash Flow | -24,867 | -12,392 | -10,834 | -9,157 | -10,092 |
| Capital Expenditure | -4,359 | -2,142 | -1,067 | -8,768 | -6,511 |
| Free Cash Flow | -29,226 | -14,534 | -11,901 | -17,925 | -16,603 |